Showing results (201-210 of 245) with videos related to
Sort By:
Pageof 25
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO studyElisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.JAMA Oncology|February 17, 2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical TrialChiara Cremolini, Carlotta Antoniotti, Sara Lonardi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.Scientific Reports|November 6, 2022
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinomaMargherita Rimini, Carles Fabregat-Franco, Valentina Burgio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONODaniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.Journal of the National Cancer Institute|September 1, 2021
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsRoberto Moretto, Andrew Elliott, Jian Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 2022
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clustersMargherita Rimini, Eleonora Loi, Carles Fabregat-Franco, et al.Oncology|August 22, 2018
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramFilippo Pietrantonio, Francesco Barretta, Valentina Fanotto, et al.Future Oncology (London, England)|October 5, 2017
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enoughLorenzo Fornaro, Valentina Fanotto, Gianna Musettini, et al.Pageof 25